Recruiting
Phase 3

Targeted Therapy vs. Chemotherapy

Sponsor:

ECOG-ACRIN Cancer Research Group

Code:

NCT06475989

Conditions

Refractory Differentiated Thyroid Gland Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Cabozantinib

Computed Tomography

Dabrafenib

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by ECOG-ACRIN Cancer Research Group on 2024-11-18.